Prognostic values of combined ratios of white blood cells in glioma: a systematic review and meta-analysis.
Glioma
Inflammatory markers
Prognostic Values
Journal
Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
23
08
2024
accepted:
18
10
2024
revised:
09
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Gliomas, the most prevalent type of neurological tumor, pose a challenging prognosis for patients. Recent studies have underscored the importance of inflammatory markers such as the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR) in predicting the prognosis of gliomas. We undertook a thorough meta-analysis to elucidate the role of these inflammatory markers in forecasting the prognosis of glioma patients. We extracted hazard ratios (HR) and their corresponding 95% confidence intervals (95% CI) from each study for analysis. To assess heterogeneity and identify influential studies, we conducted sensitivity analysis. Subgroup analysis was performed to investigate sources of heterogeneity, and we employed Egger's test to evaluate publication bias in the meta-analysis. Higher NLR levels were associated with shorter overall survival (HR = 1.46, 95% CI: 1.33-1.60) and progression-free survival (HR = 1.24, 95% CI: 1.04-1.48). There was no significant correlation between PLR levels and overall survival (HR = 1.01, 95% CI: 1.00-1.01) or progression-free survival (HR = 1.00, 95% CI: 0.98-1.02) in glioma patients. Elevated MLR levels were associated with decreased overall survival in glioma patients (HR = 1.78, 95% CI: 1.36-2.34). SII levels did not show any significant association with overall or progression-free survival in glioma patients (HR = 1.00, 95% CI: 0.99-1.01).In the sensitivity analysis, two studies potentially contributed to the instability. Subgroup analyses showed patient population and area were identified as potential sources of heterogeneity. Egger's test showed that there was publication bias in the relationship between NLR and PLR and overall survival (P < 0.05).All randomized controlled models, except for these, were not affected by publication bias. NLR and MLR are two reliable indicators of inflammation in the prognosis of glioma patients; PLR and SII do not have significant value in the prognosis of glioma patients.
Identifiants
pubmed: 39477886
doi: 10.1007/s10143-024-03064-x
pii: 10.1007/s10143-024-03064-x
doi:
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
831Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ostrom Q, Bauchet L, Davis F et al (2014) The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol 16:896–913
pubmed: 24842956
doi: 10.1093/neuonc/nou087
Ostrom Q, Patil N, Cioffi G et al (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol 22:iv1-96
pubmed: 33123732
doi: 10.1093/neuonc/noaa200
Luo YF, Deng RZ, Zhong QL, Luo DJ, Li XD, Chen XY et al (2021) The prognostic value of inflammation markers in postoperative gliomas with or without adjuvant treatments. Medicine 100(25):25
doi: 10.1097/MD.0000000000026437
Yan P, Li JW, Mo LG, Huang QR (2021) A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma. Medicine 100(47):e27972
pubmed: 34964788
doi: 10.1097/MD.0000000000027972
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
pubmed: 15758009
doi: 10.1056/NEJMoa043330
Yang P, Wang Y, Peng X et al (2013) Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. J Neurooncol 113:259–266
pubmed: 23483435
doi: 10.1007/s11060-013-1103-9
Gorlia T, van den Bent MJ, Hegi ME (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol 9:29–38
pubmed: 18082451
doi: 10.1016/S1470-2045(07)70384-4
Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 6:227–235
pubmed: 15279715
doi: 10.1215/S1152851703000620
Fekete B, Werlenius K, Örndal C, Rydenhag B (2015) Prognostic factors for glioblastoma patients—A clinical population-based study. Acta Neurol Scand. https://doi.org/10.1111/ane.12481
doi: 10.1111/ane.12481
pubmed: 26358197
Hao Y, Li X, Chen H, Huo H, Liu Z, Tian F et al (2019) A Cumulative Score Based on Preoperative Neutrophil-Lymphocyte Ratio and Fibrinogen in Predicting Overall Survival of Patients with Glioblastoma Multiforme. World neurosurgery 128:e427–e433
pubmed: 31042598
doi: 10.1016/j.wneu.2019.04.169
Carroll KT, Bryant AK, Hirshman B, Alattar AA, Joshi R, Gabel B et al (2018) Interaction between the contributions of tumor location, tumor grade, and patient age to the survival benefit associated with gross total resection. World Neurosurg 111(1878-8769(1878-8769 (Electronic)):e790–e8. https://doi.org/10.1016/j.wneu.2017.12.165
doi: 10.1016/j.wneu.2017.12.165
pubmed: 29309983
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-JonathanMoyal E et al (2017) European association for neuro-oncology (EANO) guidelineon the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18(6):e315–e329. https://doi.org/10.1016/S1470-2045(17)30194-8
doi: 10.1016/S1470-2045(17)30194-8
pubmed: 28483413
Wang P-F, Song H-W, Cai H-Q, Kong L-W, Yao K, Jiang T et al (2017) Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival. Oncotarget 8(30):50117–50123. https://doi.org/10.18632/oncotarget.15235
doi: 10.18632/oncotarget.15235
pubmed: 28223536
Huang Y, Ding H, Wu Q, Li Z, Li H, Li S et al (2019) Neutrophil-lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas. Cancer Manag Res 11:6003–6009
pubmed: 31303796
doi: 10.2147/CMAR.S202546
Pang B, Chai RC, Zhang YW, Chang YZ, Liu WH, Jia WQ et al (2021) A comprehensive model including preoperative peripheral blood inflammatory markers for prediction of the prognosis of diffuse spinal cord astrocytoma following surgery. Eur Spine J 30(10):2857–2866
pubmed: 33495960
doi: 10.1007/s00586-021-06724-4
Gandhi P, Khare R, VasudevGulwani H, Kaur S (2018) Circulatory YKL-40 & NLR: Underestimated prognostic indicators in diffuse glioma. Int J Mole Cell Med 7(2):111–118
Garrett C, Becker TM, Lynch D, Po J, Xuan W, Scott KF et al (2021) Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome. PLoS ONE 16(6):e0252614
pubmed: 34138894
doi: 10.1371/journal.pone.0252614
Yang C, Lan T, Wang Y, Huang WH, Li SM, Li J et al (2022) Cumulative scoring systems and nomograms for predicating survival in patients with glioblastomas: a study based on peripheral inflammatory markers. Front Oncol 12:716295
pubmed: 35719947
doi: 10.3389/fonc.2022.716295
Han S, Qu FW, Wang PF, Liu YX, Li SW, Yan CX (2022) Development and validation of a nomogram model based on hematological indicators for predicting the prognosis of diffused gliomas. Front Surg 9:803237
pubmed: 35495765
doi: 10.3389/fsurg.2022.803237
Wiencke JK, Koestler DC, Salas LA, Wiemels JL, Roy RP, Hansen HM et al (2017) Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival. Clin Epigenetics 9:10
pubmed: 28184256
doi: 10.1186/s13148-017-0316-8
Yang T, Mao P, Chen X, Niu X, Xu G, Bai X et al (2019) Inflammatory biomarkers in prognostic analysis for patients with glioma and the establishment of a nomogram. Oncol Lett 17(2):2516–2522
pubmed: 30719120
Lopes M, Carvalho B, Vaz R, Linhares P (2018) Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol 136(1):173–180
pubmed: 29076002
doi: 10.1007/s11060-017-2641-3
Gan Y, Zhou X, Niu X, Li J, Wang T, Zhang H et al (2019) Neutrophil/lymphocyte ratio is an independent prognostic factor in elderly patients with high-grade gliomas. World neurosurgery 127:e261–e267
pubmed: 30898756
doi: 10.1016/j.wneu.2019.03.085
Ma L, Li G, Wei M (2020) Neutrophil-to-lymphocyte ratio and its changes are related to grade II-IV glioma recurrence. Cancer Manag Res 12:9429–9434
pubmed: 33061630
doi: 10.2147/CMAR.S267523
Zhang X, Li C, Xiao LF, Gao CB, Zhao W, Yang ML et al (2020) predicting individual prognosis and grade of patients with glioma based on preoperative eosinophil and neutrophil-to-lymphocyte ratio. Cancer Manag Res 12:5793–5802
pubmed: 32765082
doi: 10.2147/CMAR.S260695
Wang PF, Meng Z, Song HW, Yao K, Duan ZJ, Yu CJ et al (2018) Preoperative changes in hematological markers and predictors of glioma grade and survival. Front Pharmacol 9:886
pubmed: 30154718
doi: 10.3389/fphar.2018.00886
Marini A, Dobran M, Aiudi D, Pesaresi A, di Somma LGM, Iacoangeli M (2020) Pre-operative hematological markers as predictive factors for overall survival and progression free survival in glioblastomas. Clin Neurol Neurosurg 197:106162
pubmed: 32890893
doi: 10.1016/j.clineuro.2020.106162
Li K, Duan WC, Zhao HB, Wang L, Wang WW, Zhan YB et al (2019) Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with the prognosis of group 3 and Group 4 medulloblastoma. Sci Rep 9(1):13239
pubmed: 31519974
doi: 10.1038/s41598-019-49733-6
Tan ZH, Shen LF, Wu HJ, Deng L, Li ZZ, Huang XQ (2019) Preoperative neutrophil/lymphocyte ratio is an independent prognostic biomarker in patients with low-grade gliomas. World neurosurgery 132:E585–E590
pubmed: 31442642
doi: 10.1016/j.wneu.2019.08.068
Weng W, Chen X, Gong S, Guo L, Zhang X (2018) Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival. Neurol Res 40(11):917–922
pubmed: 30074469
doi: 10.1080/01616412.2018.1497271
Kemerdere R, Akgun MY, Toklu S, Alizada O, Tanriverdi T (2019) Preoperative systemic inflammatory markers in low- and high-grade gliomas: A retrospective analysis of 171 patients. Heliyon 5(5):e01681
pubmed: 31193037
doi: 10.1016/j.heliyon.2019.e01681
Han S, Liu Y, Li Q, Li Z, Hou H, Wu A (2015) Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer 15:617
pubmed: 26341881
doi: 10.1186/s12885-015-1629-7
Zhang ZY, Zhan YB, Zhang FJ, Yu B, Ji YC, Zhou JQ et al (2019) Progenostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas. Aging-Us 11(16):6252–6272
doi: 10.18632/aging.102186
Wang J, Xiao W, Chen W, Hu Y (2018) Prognostic significance of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioma. EXCLI J 17:505–512
pubmed: 30034313
Kaya V, Yıldırım M, Yazıcı G, Yalçın AY, Orhan N, Güzel A (2017) Prognostic significance of indicators of systemic inflammatory responses in glioblastoma patients. Asian Pac J Cancer Prev : APJCP 18(12):3287–3291
pubmed: 29286221
Sharma P, Medhi PP, Bhattacharyya M, Nath J, Kalita AK (2023) Prognostic significance of neutrophil-lymphocyte ratio in patients of high-grade glioma undergoing adjuvant chemoradiation: a prospective study. Asian Pac J Cancer Prev: APJCP 24(10):3487–3494
pubmed: 37898854
doi: 10.31557/APJCP.2023.24.10.3487
Duan X, Yang B, Zhao C, Tie B, Cao L, Gao Y (2023) Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model. BMC Cancer 23(1):432
pubmed: 37173662
doi: 10.1186/s12885-023-10889-0
Qi Z, Cai J, Meng X, Cai S, Tang C, Lang L (2022) Prognostic value of preoperative inflammatory markers among different molecular subtypes of lower-grade glioma. J Clin Neurosci 96:180–186
pubmed: 34802893
doi: 10.1016/j.jocn.2021.10.006
Lv Y, Zhang S, Liu Z, Tian Y, Liang N, Zhang J (2019) Prognostic value of preoperative neutrophil to lymphocyte ratio is superior to systemic immune inflammation index for survival in patients with Glioblastoma. Clin Neurol Neurosurg 181:24–27
pubmed: 30974296
doi: 10.1016/j.clineuro.2019.03.017
Jarmuzek P, Kot M, Defort P, Stawicki J, Komorzycka J, Nowak K et al (2022) Prognostic values of combined ratios of white blood cells in glioblastoma: a retrospective study. J Clin Med 11(12):3397
pubmed: 35743468
doi: 10.3390/jcm11123397
Chen XY, Pan DL, Xu JH, Chen Y, Xu WF, Chen JY et al (2021) Serum inflammatory biomarkers contribute to the prognosis prediction in high-grade glioma. Front Oncol 11:754920
pubmed: 35155182
doi: 10.3389/fonc.2021.754920
Zeng T, Cui D, Gao L (2015) Glioma: an overview of current classifications, characteristics, molecular biology and target therapies. Front Biosci (Landmark Ed) 20:1104–1115
pubmed: 25961548
doi: 10.2741/4362
Bush NA, Chang SM, Berger MS (2017) Current and future strategies for treatment of glioma. Neurosurg Rev 40:1–14
pubmed: 27085859
doi: 10.1007/s10143-016-0709-8
Lei YY, Li YT, Hu QL, Wang J, Sui AX (2019) Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis. World J Surg Oncol 17(1):152
pubmed: 31472673
doi: 10.1186/s12957-019-1686-5
Wang Y, Xu C, Zhang Z (2023) Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: a meta-analysis. BMC Med 21(1):486
pubmed: 38053096
doi: 10.1186/s12916-023-03199-6
Bispo RG, Bastos Siqueira IF, de Oliveira BFS, Moreira Fernandes CE, Figueiredo LA, Cintra LP et al (2023) Prognostic value of the platelet-lymphocyte ratio for glioblastoma: a systematic review. World Neurosurg 175:137–41.e1
pubmed: 37105273
doi: 10.1016/j.wneu.2023.04.086
Zhang S, Ni Q (2023) Prognostic role of the pretreatment systemic immune-inflammation index in patients with glioma: A meta-analysis. Front Neurol 14:1094364
pubmed: 36970508
doi: 10.3389/fneur.2023.1094364
Mostofa AGM, Punganuru SR, Madala HR, Al-Obaide M, Srivenugopal KS (2017) The process and regulatory components of inflammation in brain oncogenesis. Biomolecules 7(2):34
pubmed: 28346397
doi: 10.3390/biom7020034
Shih AH, Holland EC (2006) Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 232:139–147
pubmed: 16139423
doi: 10.1016/j.canlet.2005.02.002
Cools-Lartigue J, Spicer J, McDonald B et al (2013) Neutrophyl extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest 123:3446–3458
pubmed: 23863628
doi: 10.1172/JCI67484
López-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ (2013) Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene 32:1752–60
pubmed: 22665059
doi: 10.1038/onc.2012.201
Michelson N, Rincon-Torroella J, Quiñones-Hinojosa A, Greenfield JP (2016) Exploring the role of inflammation in the malignant transformation of low-grade gliomas. J Neuroimmunol 297:132–140
pubmed: 27397086
doi: 10.1016/j.jneuroim.2016.05.019
Conti A, Gulì C, La Torre D, Tomasello C, Angileri FF, Aguennouz M (2010) Role of inflammation and oxidative stress mediators in gliomas. Cancers (Basel) 2:693–712
pubmed: 24281089
doi: 10.3390/cancers2020693
Strojnik T, Smigoc T, Lah TT (2014) Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. Anticancer Res 34:339–347
pubmed: 24403485